BridgeMD
New treatment option for Guillain-Barre Syndrome
Official title An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
ClinicalTrials.gov ID: NCT07020819
What this study is testing
What is Tanruprubart?
Tanruprubart is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for guillain-barre syndrome.
Also referred to as ANX005.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 85
You may be able to join if
- Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.
- Onset of GBS-related weakness ≤10 days before start of infusion on Day 1
- GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1. Key
You likely can't join if
- Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.
- Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes. Other protocol-defined criteria...
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Carlsbad, California, United States
- Orange, California, United States
- Aurora, Colorado, United States
- Jacksonville, Florida, United States
- Kansas City, Kansas, United States
- Shreveport, Louisiana, United States
- Worcester, Massachusetts, United States
- Detroit, Michigan, United States
- Rochester, Minnesota, United States
- Aarhus, Aarhus N, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States; Scottsdale, Arizona, United States; Carlsbad, California, United States; Orange, California, United States; Aurora, Colorado, United States; Jacksonville, Florida, United States and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.